TapewireFind a company

person · Reporting owner

Roman Michael F

Disclosed activity across 3 companies

Tapewire entity
14498
SEC CIK
0001577544

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
3M COMMM · Entity 1275Director · Chairman of the BoardFebruary 03, 2025February 18, 2025
ABBOTT LABORATORIESABT · Entity 2314DirectorSeptember 30, 2026October 03, 2026
Waystar Holding Corp.WAY · Entity 1420DirectorJune 03, 2026September 25, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

3M CO

Report date February 03, 2025 · Filed February 18, 2025 · Amendment

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect193,397.2991 Reported balance After 2025-02-03 transaction · row 1 Amendment: may correct only part of an earlier disclosure.
1 source row

Row 1 · 2025-02-03 · Tax withholding · Disposed 8,600 · Balance 193,397.2991

F1: The number of shares previously reported as being withheld for the payment of taxes was estimated. This amendment is being filed to update the Form 4 with the actual number of shares withheld.

Filing footnotes · ownership attribution and instrument terms

F1: The number of shares previously reported as being withheld for the payment of taxes was estimated. This amendment is being filed to update the Form 4 with the actual number of shares withheld.

ABBOTT LABORATORIES

Report date September 30, 2026 · Filed October 03, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Equivalent UnitsSEC Table II · derivative / convertible securityDirect7,166 Reported balance After 2026-09-30 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-09-30 · Grant · Acquired 381 · Balance 7,166

F1: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F2: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

Filing footnotes · ownership attribution and instrument terms

F1: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F2: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

Waystar Holding Corp.

Report date June 03, 2026 · Filed September 25, 2026 · Amendment

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect15,580 Reported balance After 2026-06-03 transaction · row 1 Amendment: may correct only part of an earlier disclosure.
1 source row

Row 1 · 2026-06-03 · Grant · Acquired 10,446 · Balance 15,580

F1: Reflects a grant of restricted stock units ("RSUs") which vest on the earlier of (i) June 1, 2027 and (ii) the first regularly scheduled annual meeting of the stockholders following the grant date. Each RSU represents a contingent right to receive one share of Common Stock upon settlement. This amended Form 4 is being filed solely to correct the number of RSUs granted from 9,303 to 10,446.

F2: Includes unvested RSUs.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects a grant of restricted stock units ("RSUs") which vest on the earlier of (i) June 1, 2027 and (ii) the first regularly scheduled annual meeting of the stockholders following the grant date. Each RSU represents a contingent right to receive one share of Common Stock upon settlement. This amended Form 4 is being filed solely to correct the number of RSUs granted from 9,303 to 10,446.

F2: Includes unvested RSUs.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
January 24, 2025 Filed Jan 27, 2025 13:57 UTC 3M CO MMM · Entity 1275 SaleCommon Stock 9,100 $150.04 $1,365,318.50
Disclosure

SEC source: 0001127602-25-001991 · form4.xml · nonDerivative · entry 7

Roman Michael F · CIK 0001577544 · Director · Chairman of the Board

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 176,923.0713

Read SEC document
January 24, 2025 Filed Jan 27, 2025 13:57 UTC 3M CO MMM · Entity 1275 SaleCommon Stock 200 $150.03 $30,005.00
Disclosure

SEC source: 0001127602-25-001991 · form4.xml · nonDerivative · entry 6

Roman Michael F · CIK 0001577544 · Director · Chairman of the Board

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 186,023.0713

Read SEC document
January 24, 2025 Filed Jan 27, 2025 13:57 UTC 3M CO MMM · Entity 1275 SaleCommon Stock 947 $150.02 $142,068.94
Disclosure

SEC source: 0001127602-25-001991 · form4.xml · nonDerivative · entry 5

Roman Michael F · CIK 0001577544 · Director · Chairman of the Board

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 186,223.0713

Read SEC document
January 24, 2025 Filed Jan 27, 2025 13:57 UTC 3M CO MMM · Entity 1275 SaleCommon Stock 8,321 $150.01 $1,248,233.21
Disclosure

SEC source: 0001127602-25-001991 · form4.xml · nonDerivative · entry 4

Roman Michael F · CIK 0001577544 · Director · Chairman of the Board

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 187,170.0713

Read SEC document
January 24, 2025 Filed Jan 27, 2025 13:57 UTC 3M CO MMM · Entity 1275 SaleCommon Stock 100 $150.01 $15,000.50
Disclosure

SEC source: 0001127602-25-001991 · form4.xml · nonDerivative · entry 3

Roman Michael F · CIK 0001577544 · Director · Chairman of the Board

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 195,491.0713

Read SEC document
January 24, 2025 Filed Jan 27, 2025 13:57 UTC 3M CO MMM · Entity 1275 SaleCommon Stock 25,403 $150.00 $3,810,450.00
Disclosure

SEC source: 0001127602-25-001991 · form4.xml · nonDerivative · entry 2

Roman Michael F · CIK 0001577544 · Director · Chairman of the Board

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 195,591.0713

Read SEC document
January 24, 2025 Filed Jan 27, 2025 13:57 UTC 3M CO MMM · Entity 1275 Exercise / conversionCommon Stock 45,276 $146.05 $6,612,559.80
Disclosure

SEC source: 0001127602-25-001991 · form4.xml · nonDerivative · entry 1

Roman Michael F · CIK 0001577544 · Director · Chairman of the Board

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 220,994.0713

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
December 31, 2024 Filed Jan 3, 2025 22:19 UTC ABBOTT LABORATORIES ABT · Entity 2314 GrantStock Equivalent Units · Derivative 311 $113.11 $35,177.21
Disclosure

SEC source: 0001415889-25-000575 · form4-01032025_100102.xml · derivative · entry 1

Roman Michael F · CIK 0001577544 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,670

Underlying: Common Shares · 311 shares

Expires not disclosed

F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

Read SEC document
September 30, 2024 Filed Oct 1, 2024 21:39 UTC ABBOTT LABORATORIES ABT · Entity 2314 GrantStock Equivalent Units · Derivative 309 $114.01 $35,229.09
Disclosure

SEC source: 0001415889-24-024240 · form4-10012024_091021.xml · derivative · entry 1

Roman Michael F · CIK 0001577544 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,338

Underlying: Common Shares · 309 shares

Expires not disclosed

F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

Read SEC document
August 07, 2024 Filed Aug 8, 2024 12:02 UTC 3M CO MMM · Entity 1275 SaleCommon Stock 482 $123.48 $59,517.36
Disclosure

SEC source: 0001127602-24-021839 · form4.xml · nonDerivative · entry 4

Roman Michael F · CIK 0001577544 · Director · Chairman of the Board

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 174,035.5568

F1 · balance_after: Includes dividend share equivalents, accrued quarterly, pursuant to 3M's Deferred Compensation Plan.

Read SEC document
August 07, 2024 Filed Aug 8, 2024 12:02 UTC 3M CO MMM · Entity 1275 SaleCommon Stock 443 $123.47 $54,697.21
Disclosure

SEC source: 0001127602-24-021839 · form4.xml · nonDerivative · entry 3

Roman Michael F · CIK 0001577544 · Director · Chairman of the Board

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 174,517.5568

Read SEC document
August 07, 2024 Filed Aug 8, 2024 12:02 UTC 3M CO MMM · Entity 1275 SaleCommon Stock 611 $123.46 $75,434.06
Disclosure

SEC source: 0001127602-24-021839 · form4.xml · nonDerivative · entry 2

Roman Michael F · CIK 0001577544 · Director · Chairman of the Board

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 174,960.5568

Read SEC document
August 07, 2024 Filed Aug 8, 2024 12:02 UTC 3M CO MMM · Entity 1275 SaleCommon Stock 4,139 $123.45 $510,959.55
Disclosure

SEC source: 0001127602-24-021839 · form4.xml · nonDerivative · entry 1

Roman Michael F · CIK 0001577544 · Director · Chairman of the Board

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 175,571.5568

Read SEC document
June 30, 2024 Filed Jul 2, 2024 20:30 UTC ABBOTT LABORATORIES ABT · Entity 2314 GrantStock Equivalent Units · Derivative 339 $103.91 $35,225.49
Disclosure

SEC source: 0001415889-24-018914 · form4-07022024_080740.xml · derivative · entry 1

Roman Michael F · CIK 0001577544 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,009

Underlying: Common Shares · 339 shares

Expires not disclosed

F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

Read SEC document
May 03, 2024 Filed May 6, 2024 22:56 UTC 3M CO MMM · Entity 1275 GrantNon-qualified Stock Option (Right to Buy) · Derivative 316,644 $97.10 Strike: $97.15 $30,746,132.40
Disclosure

SEC source: 0001127602-24-014349 · form4.xml · derivative · entry 1

Roman Michael F · CIK 0001577544 · Director · Chairman of the Board

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 316,644

Underlying: Common Stock · 316,644 shares

Expires 2034-05-02

F1 · derivative.exercise_date: The stock option will vest and become exercisable in a series of three equal annual installments beginning on February 6, 2025.

Read SEC document
April 26, 2024 Filed Apr 30, 2024 22:16 UTC ABBOTT LABORATORIES ABT · Entity 2314 GrantCommon shares without par value 1,866 $0.00 $0.00
Disclosure

SEC source: 0001415889-24-011799 · form4-04302024_100430.xml · nonDerivative · entry 1

Roman Michael F · CIK 0001577544 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,843

F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

Read SEC document
March 31, 2024 Filed Apr 2, 2024 22:50 UTC ABBOTT LABORATORIES ABT · Entity 2314 GrantStock Equivalent Units · Derivative 310 $113.66 $35,234.60
Disclosure

SEC source: 0001415889-24-009863 · form4-04022024_100413.xml · derivative · entry 1

Roman Michael F · CIK 0001577544 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,650

Underlying: Common Shares · 310 shares

Expires not disclosed

F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

Read SEC document
February 05, 2024 Filed Feb 6, 2024 19:40 UTC 3M CO MMM · Entity 1275 Tax withholdingCommon Stock 601 $0.00 $0.00
Disclosure

SEC source: 0001127602-24-003525 · form4.xml · nonDerivative · entry 2

Roman Michael F · CIK 0001577544 · Director · Chairman and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 157,711.2602

F4 · shares: The number of shares withheld for taxes was estimated and will be revised by amendment if necessary.

Read SEC document
February 05, 2024 Filed Feb 6, 2024 19:40 UTC 3M CO MMM · Entity 1275 GrantCommon Stock 24,954.272 $0.00 $0.00
Disclosure

SEC source: 0001127602-24-003525 · form4.xml · nonDerivative · entry 1

Roman Michael F · CIK 0001577544 · Director · Chairman and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 158,312.2602

F1 · shares: Represents shares of 3M common stock that will be delivered pursuant to the terms of a performance share award made to the reporting person on March 1, 2021. The performance-based vesting requirements applicable to such award were satisfied on the date reported in Column 2 above, which represents the date on which the level of performance attained was certified. The reporting person previously elected to defer receipt of the shares and will not have voting or investment powers with respect to such shares until they are issued.

F2 · balance_after: Includes dividend share equivalents, accrued quarterly, pursuant to 3M's Deferred Compensation Plan.

F3 · balance_after: Includes shares acquired under 3M's General Employee Stock Purchase Plan.

Read SEC document
February 05, 2024 Filed Feb 15, 2024 19:38 UTC Amendment 3M CO MMM · Entity 1275 Tax withholdingCommon Stock 791.403 $0.00 $0.00
Disclosure

SEC source: 0001127602-24-005173 · form4a.xml · nonDerivative · entry 1

Roman Michael F · CIK 0001577544 · Director · Chairman and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 157,520.8572

F1 · shares: The number of shares previously reported as being withheld for the payment of taxes was estimated. This amendment is being filed to update the Form 4 with the actual number of shares withheld.

Read SEC document
December 31, 2023 Filed Jan 3, 2024 22:33 UTC ABBOTT LABORATORIES ABT · Entity 2314 GrantStock Equivalent Units · Derivative 320 $110.07 $35,222.40
Disclosure

SEC source: 0001415889-24-000362 · form4-01032024_100152.xml · derivative · entry 1

Roman Michael F · CIK 0001577544 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,324

Underlying: Common Shares · 320 shares

Expires not disclosed

F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

Read SEC document
September 30, 2023 Filed Oct 3, 2023 22:48 UTC ABBOTT LABORATORIES ABT · Entity 2314 GrantStock Equivalent Units · Derivative 363 $96.85 $35,156.55
Disclosure

SEC source: 0001415889-23-013949 · form4-10032023_101048.xml · derivative · entry 1

Roman Michael F · CIK 0001577544 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,988

Underlying: Common Shares · 363 shares

Expires not disclosed

F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

Read SEC document
June 30, 2023 Filed Jul 5, 2023 15:57 UTC ABBOTT LABORATORIES ABT · Entity 2314 GrantStock Equivalent Units · Derivative 316 $109.02 $34,450.32
Disclosure

SEC source: 0001104659-23-077924 · tm2320556-4_4seq1.xml · derivative · entry 1

Roman Michael F · CIK 0001577544 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,612

Underlying: Common Shares · 316 shares

Expires not disclosed

F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

Read SEC document
April 28, 2023 Filed May 3, 2023 00:02 UTC ABBOTT LABORATORIES ABT · Entity 2314 GrantCommon shares without par value 1,816 $0.00 $0.00
Disclosure

SEC source: 0001415889-23-007138 · form4-05032023_120557.xml · nonDerivative · entry 1

Roman Michael F · CIK 0001577544 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,977

F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

F2 · balance_after: Includes 60 shares that were acquired before Mr. Roman became an Abbott director and were not previously reported.

Read SEC document
March 31, 2023 Filed Apr 4, 2023 23:29 UTC ABBOTT LABORATORIES ABT · Entity 2314 GrantStock Equivalent Units · Derivative 325 $101.26 $32,909.50
Disclosure

SEC source: 0001415889-23-006151 · form4-04042023_110437.xml · derivative · entry 1

Roman Michael F · CIK 0001577544 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,285

Underlying: Common Shares · 325 shares

Expires not disclosed

F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

Read SEC document
February 07, 2023 Filed Feb 8, 2023 22:11 UTC 3M CO MMM · Entity 1275 GrantNon-qualified Stock Option (Right to Buy) · Derivative 269,995 $0.00 Strike: $116.90 $0.00
Disclosure

SEC source: 0001127602-23-004044 · form4.xml · derivative · entry 3

Roman Michael F · CIK 0001577544 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 269,995

Underlying: Common Stock · 269,995 shares

Expires 2033-02-07

F5 · derivative.exercise_date: The stock option will vest and become exercisable in a series of three equal installments on each of the first, second and third anniversary of the grant date.

Read SEC document
February 06, 2023 Filed Feb 8, 2023 22:11 UTC 3M CO MMM · Entity 1275 Tax withholdingCommon Stock 844.743 $0.00 $0.00
Disclosure

SEC source: 0001127602-23-004044 · form4.xml · nonDerivative · entry 2

Roman Michael F · CIK 0001577544 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 127,140.4576

F4 · shares: The number of shares withheld for taxes was estimated and will be revised by amendment if necessary.

Read SEC document
February 06, 2023 Filed Feb 8, 2023 22:11 UTC 3M CO MMM · Entity 1275 GrantCommon Stock 35,281.349 $0.00 $0.00
Disclosure

SEC source: 0001127602-23-004044 · form4.xml · nonDerivative · entry 1

Roman Michael F · CIK 0001577544 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 127,985.2006

F1 · shares: Represents shares of 3M common stock that will be delivered pursuant to the terms of a performance share award made to the reporting person on March 1, 2020. The performance-based vesting requirements applicable to such award were satisfied on the date reported in Column 2, which represents the date on which the level of performance attained was certified. The reporting person previously elected to defer receipt of the shares and will not have voting or investment powers with respect to such shares until they are issued.

F2 · balance_after: Includes shares acquired under 3M's General Employee Stock Purchase Plan.

F3 · balance_after: Includes dividend share equivalents, accrued quarterly, pursuant to 3M's Deferred Compensation Plan.

Read SEC document
February 06, 2023 Filed Feb 21, 2023 13:59 UTC Amendment 3M CO MMM · Entity 1275 Tax withholdingCommon Stock 1,139.996 $0.00 $0.00
Disclosure

SEC source: 0001127602-23-006072 · form4a.xml · nonDerivative · entry 1

Roman Michael F · CIK 0001577544 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 126,845.2046

F1 · shares: The number of shares previously reported as being withheld for the payment of taxes was estimated. This amendment is being filed to update the Form 4 with the actual number of shares withheld.

Read SEC document
December 31, 2022 Filed Jan 4, 2023 23:15 UTC ABBOTT LABORATORIES ABT · Entity 2314 GrantStock Equivalent Units · Derivative 300 $109.79 $32,937.00
Disclosure

SEC source: 0001415889-23-000437 · form4-01042023_110104.xml · derivative · entry 1

Roman Michael F · CIK 0001577544 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,949

Underlying: Common Shares · 300 shares

Expires not disclosed

F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

Read SEC document
September 30, 2022 Filed Oct 4, 2022 21:26 UTC ABBOTT LABORATORIES ABT · Entity 2314 GrantStock Equivalent Units · Derivative 341 $96.76 $32,995.16
Disclosure

SEC source: 0001415889-22-010265 · form4-10042022_021057.xml · derivative · entry 1

Roman Michael F · CIK 0001577544 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,641

Underlying: Common Shares · 341 shares

Expires not disclosed

F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

Read SEC document
June 30, 2022 Filed Jul 1, 2022 20:26 UTC ABBOTT LABORATORIES ABT · Entity 2314 GrantStock Equivalent Units · Derivative 303 $108.65 $32,920.95
Disclosure

SEC source: 0001415889-22-007173 · form4-07012022_010742.xml · derivative · entry 1

Roman Michael F · CIK 0001577544 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,295

Underlying: Common Shares · 303 shares

Expires not disclosed

F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

Read SEC document
May 03, 2022 Filed May 4, 2022 14:49 UTC 3M CO MMM · Entity 1275 Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative 10,610 $0.00 Strike: $101.49 $0.00
Disclosure

SEC source: 0001127602-22-013149 · form4.xml · derivative · entry 3

Roman Michael F · CIK 0001577544 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,610 shares

Expires 2023-02-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 03, 2022 Filed May 4, 2022 14:49 UTC 3M CO MMM · Entity 1275 SaleCommon Stock 10,610 $146.21 $1,551,288.10
Disclosure

SEC source: 0001127602-22-013149 · form4.xml · nonDerivative · entry 2

Roman Michael F · CIK 0001577544 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,360.7475

F1 · shares: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 30, 2021.

F2 · balance_after: Includes dividend share equivalents, accrued quarterly, pursuant to 3M's Deferred Compensation Plan.

F3 · balance_after: Includes shares acquired under 3M's General Employee Stock Purchase Plan.

Read SEC document
May 03, 2022 Filed May 4, 2022 14:49 UTC 3M CO MMM · Entity 1275 Exercise / conversionCommon Stock 10,610 $101.49 $1,076,808.90
Disclosure

SEC source: 0001127602-22-013149 · form4.xml · nonDerivative · entry 1

Roman Michael F · CIK 0001577544 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,970.7475

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 30, 2021.

Read SEC document
April 29, 2022 Filed May 3, 2022 22:18 UTC ABBOTT LABORATORIES ABT · Entity 2314 GrantCommon shares without par value 1,602 $0.00 $0.00
Disclosure

SEC source: 0001415889-22-004553 · form4-05032022_030519.xml · nonDerivative · entry 1

Roman Michael F · CIK 0001577544 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,101

F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

Read SEC document
March 31, 2022 Filed Apr 1, 2022 21:24 UTC ABBOTT LABORATORIES ABT · Entity 2314 GrantStock Equivalent Units · Derivative 278 $118.36 $32,904.08
Disclosure

SEC source: 0001415889-22-003592 · form4-04012022_020434.xml · derivative · entry 1

Roman Michael F · CIK 0001577544 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 987

Underlying: Common Shares · 278 shares

Expires not disclosed

F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

Read SEC document
February 08, 2022 Filed Feb 9, 2022 23:45 UTC 3M CO MMM · Entity 1275 GrantNon-qualified Stock Option (Right to Buy) · Derivative 217,083 $0.00 Strike: $162.41 $0.00
Disclosure

SEC source: 0001127602-22-004050 · form4.xml · derivative · entry 3

Roman Michael F · CIK 0001577544 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 217,083

Underlying: Common Stock · 217,083 shares

Expires 2032-02-06

F5 · derivative.exercise_date: The stock option will vest and become exercisable in a series of three equal installments on each of the first, second and third anniversary of the grant date.

Read SEC document
February 07, 2022 Filed Feb 9, 2022 23:45 UTC 3M CO MMM · Entity 1275 Tax withholdingCommon Stock 558.862 $0.00 $0.00
Disclosure

SEC source: 0001127602-22-004050 · form4.xml · nonDerivative · entry 2

Roman Michael F · CIK 0001577544 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 89,804.0188

F4 · shares: The number of shares withheld for taxes was estimated and will be revised by amendment if necessary.

Read SEC document
February 07, 2022 Filed Feb 9, 2022 23:45 UTC 3M CO MMM · Entity 1275 GrantCommon Stock 23,427.52 $0.00 $0.00
Disclosure

SEC source: 0001127602-22-004050 · form4.xml · nonDerivative · entry 1

Roman Michael F · CIK 0001577544 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,362.8808

F1 · shares: Represents shares of 3M common stock that will be delivered pursuant to the terms of a performance share award made to the reporting person on March 1, 2019. The performance-based vesting requirements applicable to such award were satisfied on the date reported in Column 2 above, which represents the date on which the level of performance attained was certified. The reporting person previously elected to defer receipt of the shares and will not have voting or investment powers with respect to such shares until they are issued.

F2 · balance_after: Includes shares acquired under 3M's General Employee Stock Purchase Plan.

F3 · balance_after: Includes dividend share equivalents, accrued quarterly, pursuant to 3M's Deferred Compensation Plan.

Read SEC document
February 07, 2022 Filed Feb 22, 2022 14:34 UTC Amendment 3M CO MMM · Entity 1275 Tax withholdingCommon Stock 754.036 $0.00 $0.00
Disclosure

SEC source: 0001127602-22-005844 · form4a.xml · nonDerivative · entry 1

Roman Michael F · CIK 0001577544 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 89,608.8448

F1 · shares: The number of shares previously reported as being withheld for the payment of taxes was estimated. This amendment is being filed to update the Form 4 with the actual number of shares withheld.

Read SEC document
December 31, 2021 Filed Jan 4, 2022 22:27 UTC ABBOTT LABORATORIES ABT · Entity 2314 GrantStock Equivalent Units · Derivative 234 $140.74 $32,933.16
Disclosure

SEC source: 0001415889-22-000238 · form4-01042022_020103.xml · derivative · entry 1

Roman Michael F · CIK 0001577544 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 705

Underlying: Common Shares · 234 shares

Expires not disclosed

F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

Read SEC document
September 30, 2021 Filed Oct 4, 2021 21:41 UTC ABBOTT LABORATORIES ABT · Entity 2314 GrantStock Equivalent Units · Derivative 279 $118.13 $32,958.27
Disclosure

SEC source: 0001415889-21-004715 · form4-10042021_021035.xml · derivative · entry 1

Roman Michael F · CIK 0001577544 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 469

Underlying: Common Shares · 279 shares

Expires not disclosed

F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

Read SEC document
July 30, 2021 Filed Jan 6, 2022 20:05 UTC 3M CO MMM · Entity 1275 GiftCommon Stock 1,290 $0.00 $0.00
Disclosure

SEC source: 0001127602-22-001070 · form5.xml · nonDerivative · entry 1

Roman Michael F · CIK 0001577544 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,860.7834

Read SEC document
June 30, 2021 Filed Jul 2, 2021 21:05 UTC ABBOTT LABORATORIES ABT · Entity 2314 GrantStock Equivalent Units · Derivative 189 $115.93 $21,910.77
Disclosure

SEC source: 0001415889-21-003423 · form4-07022021_020728.xml · derivative · entry 1

Roman Michael F · CIK 0001577544 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 189

Underlying: Common Shares · 189 shares

Expires not disclosed

F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

Read SEC document
May 03, 2021 Filed May 4, 2021 14:45 UTC 3M CO MMM · Entity 1275 Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative 9,747 $0.00 Strike: $87.89 $0.00
Disclosure

SEC source: 0001127602-21-015059 · form4.xml · derivative · entry 3

Roman Michael F · CIK 0001577544 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,747 shares

Expires 2022-02-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · security: This option becomes exercisable in equal installments on each of the first three anniversaries of the grant date (2/7/2012).

Read SEC document
May 03, 2021 Filed May 4, 2021 14:45 UTC 3M CO MMM · Entity 1275 SaleCommon Stock 6,803 $197.80 $1,345,599.39
Disclosure

SEC source: 0001127602-21-015059 · form4.xml · nonDerivative · entry 2

Roman Michael F · CIK 0001577544 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,114.5329

F1 · shares: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 17, 2020.

F2 · balance_after: Includes shares acquired under 3M's General Employee Stock Purchase Plan.

F3 · balance_after: Includes shares acquired pursuant to 3M's Dividend Reinvestment Plan.

Read SEC document
May 03, 2021 Filed May 4, 2021 14:45 UTC 3M CO MMM · Entity 1275 Exercise / conversionCommon Stock 9,747 $87.89 $856,663.83
Disclosure

SEC source: 0001127602-21-015059 · form4.xml · nonDerivative · entry 1

Roman Michael F · CIK 0001577544 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,917.5329

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 17, 2020.

Read SEC document
April 23, 2021 Filed Apr 27, 2021 23:13 UTC ABBOTT LABORATORIES ABT · Entity 2314 GrantCommon shares without par value 1,499 $0.00 $0.00
Disclosure

SEC source: 0001415889-21-002162 · form4-04272021_040408.xml · nonDerivative · entry 1

Roman Michael F · CIK 0001577544 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,499

F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

Read SEC document
February 02, 2021 Filed Feb 4, 2021 01:15 UTC 3M CO MMM · Entity 1275 GrantNon-qualified Stock Option (Right to Buy) · Derivative 207,302 $0.00 Strike: $175.02 $0.00
Disclosure

SEC source: 0001127602-21-003870 · form4.xml · derivative · entry 3

Roman Michael F · CIK 0001577544 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 207,302

Underlying: Common Stock · 207,302 shares

Expires 2031-02-01

F5 · derivative.exercise_date: The stock option will vest and become exercisable in a series of three equal installments on each of the first, second and third anniversary of the grant date.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.